Product Description: Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).
Applications: Cancer-Kinase/protease
Formula: C25H24FN7O4
References: [1]Nakaya Y, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011 Jul;1(7):e29./[2]Kuroda J, et al. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24.
CAS Number: 1354799-87-3
Molecular Weight: 505.50
Compound Purity: 99.87
Research Area: Cancer
Solubility: DMSO : ≥ 30 mg/mL/H2O : < 0.1 mg/mL
Target: JAK
English
Deutsch
